110 related articles for article (PubMed ID: 23261218)
1. The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.
Zhu S; Wonganan P; Lansakara-P DS; O'Mary HL; Li Y; Cui Z
Biomaterials; 2013 Mar; 34(9):2327-39. PubMed ID: 23261218
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
Zhu S; Lansakara-P DS; Li X; Cui Z
Bioconjug Chem; 2012 May; 23(5):966-80. PubMed ID: 22471294
[TBL] [Abstract][Full Text] [Related]
3. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
4. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
Chung WG; Sandoval MA; Sloat BR; Lansakara-P DS; Cui Z
J Control Release; 2012 Jan; 157(1):132-40. PubMed ID: 21851843
[TBL] [Abstract][Full Text] [Related]
5. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
[TBL] [Abstract][Full Text] [Related]
6. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
[TBL] [Abstract][Full Text] [Related]
7. Preparation, optimization and in vitro characterization of stearoyl-gemcitabine polymeric micelles: a comparison with its self-assembled nanoparticles.
Daman Z; Ostad S; Amini M; Gilani K
Int J Pharm; 2014 Jul; 468(1-2):142-51. PubMed ID: 24731731
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of gemcitabine prodrug along with anti NF-κB siRNA by tri-layer micelles can increase cytotoxicity, uptake and accumulation of the system in the cancers.
Norouzi P; Amini M; Dinarvand R; Arefian E; Seyedjafari E; Atyabi F
Mater Sci Eng C Mater Biol Appl; 2020 Nov; 116():111161. PubMed ID: 32806226
[TBL] [Abstract][Full Text] [Related]
9. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Lansakara-P DS; Rodriguez BL; Cui Z
Int J Pharm; 2012 Jun; 429(1-2):123-34. PubMed ID: 22425885
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
Jordheim LP; Guittet O; Lepoivre M; Galmarini CM; Dumontet C
Mol Cancer Ther; 2005 Aug; 4(8):1268-76. PubMed ID: 16093443
[TBL] [Abstract][Full Text] [Related]
12. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.
Wang Y; Fan W; Dai X; Katragadda U; Mckinley D; Teng Q; Tan C
Mol Pharm; 2014 Apr; 11(4):1140-50. PubMed ID: 24579673
[TBL] [Abstract][Full Text] [Related]
13. Effect of surface mannosylation on the cytotoxicity and cellular uptake of stearoyl gemcitabine-incorporated, acid-sensitive micelles.
Alzhrani RF; Xu H; Valdes SA; Naguib YW; Cui Z
Colloid Interface Sci Commun; 2021 Jul; 43():. PubMed ID: 34307073
[TBL] [Abstract][Full Text] [Related]
14. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
[TBL] [Abstract][Full Text] [Related]
15. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.
Chen Z; Zhou J; Zhang Y; Bepler G
Biochem Biophys Res Commun; 2011 Sep; 413(2):383-8. PubMed ID: 21893046
[TBL] [Abstract][Full Text] [Related]
17. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.
De Angel RE; Blando JM; Hogan MG; Sandoval MA; Lansakara-P DS; Dunlap SM; Hursting SD; Cui Z
Cancer Biol Ther; 2013 Apr; 14(4):357-64. PubMed ID: 23358472
[TBL] [Abstract][Full Text] [Related]
18. The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Labroli MA; Dwyer MP; Shen R; Popovici-Muller J; Pu Q; Wyss D; McCoy M; Barrett D; Davis N; Seghezzi W; Shanahan F; Taricani L; Beaumont M; Malinao MC; Parry D; Guzi TJ
Bioorg Med Chem; 2014 Apr; 22(7):2303-10. PubMed ID: 24588962
[TBL] [Abstract][Full Text] [Related]
19. Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Smid K; Bergman AM; Eijk PP; Veerman G; van Haperen VW; van den Ijssel P; Ylstra B; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1001-7. PubMed ID: 17065054
[TBL] [Abstract][Full Text] [Related]
20. A nanoparticle depot formulation of 4-(N)-stearoyl gemcitabine shows a strong anti-tumour activity.
Zhu S; Li X; Lansakara-P DS; Kumar A; Cui Z
J Pharm Pharmacol; 2013 Feb; 65(2):236-42. PubMed ID: 23278691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
